Mitoxantrone injections (Mx), VUFB Prague, were administered to 24 patients with acute myeloid leukaemia (AML) and non-Hodgkin lymphoma (NHL). Patients with NHL were treated by monotherapy with Mx or by polychemotherapy in combination with CMOP (cyclophosphamide, mitoxantrone, vincristine, prednisone). To patients with AML Mx was administered 1x during induction treatment as monotherapy, in the remaining nine patients as post-remission treatment or re-induction treatment in combination with medium doses of cytosine arabinoside (IDAC + Mx). A positive therapeutic effect was observed in NHL with a high or medium degree of malignity during primary as well as during secondary treatment. Very good therapeutic results with Mx were achieved in AML in induction, post-remission and even re-induction treatment with a minimal haematological and non-haematological toxicity.

Keywords: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols /therapeutic use/; Female; Humans; Leukemia, Myeloid /drug therapy/; Lymphoma, Non-Hodgkin /drug therapy/; Male; Middle Aged; Mitoxantrone /administration & dosage/